Summarized by Masters of Longevity from PR Newswire.
Report of positive post-authorization efficacy and safety results for an IgG‑cleaving therapy enabling transplantation in highly sensitized kidney patients presented at a major nephrology meeting.
Key Takeaways
- Imlifidase have a conditional approval in Europe since 2020.
- The primary trial objective was to assess graft failure-free survival at 1 year after transplantation.
- There are approximately 170,000 kidney patients in the U.S.
